...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Canadian Journal of Physiology and Pharmacology >Sorafenib-loaded PAMAM dendrimer attenuates liver fibrosis and its complications in bile-duct-ligated rats
【24h】

Sorafenib-loaded PAMAM dendrimer attenuates liver fibrosis and its complications in bile-duct-ligated rats

机译：Sorafenib加载的PAMAM树枝状蛋白衰减肝脏纤维化及其在胆管连接的大鼠中的并发症

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

We assessed the effect of sorafenib-loaded polyamidoamine (PAMAM) dendrimer on liver fibrosis induced by bile duct ligation (BDL). Male Wistar rats were divided into 9 groups: intact, sham, DMSO + BDL, BDL, sorafenib (30 mg/kg), sorafenib (60 mg/kg), PAMAM + BDL, sorafenib (30 mg/kg) + PAMAM + BDL, sorafenib (60 mg/kg) + PAMAM + BDL. BDL was induced and then rats were treated daily with sorafenib and (or) PAMAM for 4 weeks. Improvement of liver was detected via assessment of ascites formation, collagen deposition, liver blood flow, vascular endothelial growth factor level, and blood cells count. Sorafenib-loaded PAMAM dendrimer in both 30 and 60 mg/kg doses reduced ascites formation, reduced collagen deposition, and improved drug-induced hematological side effects of sorafenib alone in comparison with sorafenib-alone treatment. Sorafenib-loaded PAMAM dendrimer increased liver blood flow compared with sorafenib-received groups. Sorafenib-loaded PAMAM dendrimer reduced BDL-induced liver injury compared with sorafenib-received groups. Moreover, sorafenib-loaded PAMAM dendrimer decreased vascular endothelial growth factor level in serum and liver tissue in comparison with sorafenib-received groups. Sorafenib-loaded PAMAM dendrimer profoundly improved the therapeutic effects of sorafenib in BDL rats.
机译：我们评估了索拉非苯基加入的聚酰胺（PAMAM）树突（PAMAM）树枝状仪对胆管结扎（BDL）诱导的肝纤维化的影响。雄性Wistar大鼠分为9组：完整，假，DMSO + BDL，BDL，Sorafenib（30mg / kg），索拉非尼（60 mg / kg），PAMAM + BDL，Sorafenib（30 mg / kg）+ PAMAM + BDL ，索拉芬（60 mg / kg）+ pamam + bdl。诱导BDL，然后用索拉非尼和（或）帕姆每天进行大鼠4周。通过评估腹水形成，胶原沉积，肝血流量，血管内皮生长因子水平和血细胞计数来检测肝脏的改善。在30和60mg / kg / kg的索拉非尼加载的PAMAM树枝状剂减少了腹水形成，降低胶原沉积，并单独改善索拉非尼的药物诱导的血液学副作用，与Sorafenib单独处理相比。与索拉非尼接受的组相比，Sorafenib装载的PAMAM Dendrimer增加了肝脏血流量。与Sorafenib接受的组相比，Sorafenib装载的PAMAM Dendrimer降低了BDL诱导的肝损伤。此外，与Sorafenib接受的基团相比，Sorafenib负载的PAMAM树枝状细胞降低血清和肝组织中的血管内皮生长因子水平。索拉非尼加载的PAMAM Dendrimer深刻改善了Sorafenib在BDL大鼠中的治疗效果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号